Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Both tested doses improved the primary skin disease activity endpoint versus placebo over 16 weeks.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Priovant, a Roivant (ROIV) company, announced publication of Phase 2 brepocitinib results in cutaneous sarcoidosis in JAMA Dermatology. The randomized, placebo-controlled study enrolled 31 adults for 16 weeks. The primary endpoint, change in a skin disease activity score, improved by 22.3 points with 45 mg daily and 22.2 points with 15 mg, versus 0.7 points with placebo; both comparisons had P<0.0001.
At Week 16, 69% receiving 45 mg achieved clear or almost clear skin with at least a two-category improvement, versus 0% on placebo. Improvements appeared by Week 4 and increased through Week 16. Skin-related quality of life also improved, and no serious adverse events occurred during treatment. Priovant is evaluating 45 mg daily in the ongoing Phase 3 BEACON+ study and expects topline data in calendar year 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPrimary endpoint improved 22.3 points with 45 mg and 22.2 with 15 mg versus 0.7 with placebo at Week 16.
- Minor pointClear or almost clear skin with at least two-category improvement: 69% on 45 mg versus 0% placebo at Week 16.
- Minor pointAt least 50% skin activity improvement: 76.9% on 45 mg versus 0% placebo at Week 16.
- Minor pointAt least 10-point skin activity improvement: 100% on 45 mg versus 14.3% placebo at Week 16.
- Minor pointSkin activity score below 5: 61.5% on 45 mg versus 0% placebo at Week 16.
6 minor points
- Minor pointSkindex-16 quality-of-life score improved 23.5 points on 45 mg versus 8.9-point worsening on placebo at Week 16.
- Minor pointPatient-reported improvement occurred in all 45 mg participants versus 29% on placebo.
- Minor pointSkin disease improvements appeared by Week 4 and increased through Week 16.
- Minor pointPost hoc analyses suggested dose-dependent benefit in participants with lupus pernio, a form of cutaneous sarcoidosis.
- Minor pointNo serious adverse events occurred during the 16-week treatment period.
- Minor point. Forward-looking: it has not happened yet and may not happen.Phase 3 BEACON+ is ongoing; Priovant expects topline data in calendar year 2028.
Negative
- None.
News Explained
The BEACON+ Phase 3 is enrolling about 140 patients at roughly 70 sites worldwide, with 3:2 randomization to brepocitinib 45 mg once daily or placebo; its primary endpoint is the share achieving at least a
AI-generated analysis. How Rhea-AI works. Not financial advice.
- At Week 16,
69% of participants receiving brepocitinib 45 mg achieved "Clear" or "Almost Clear" skin, with at least a 2-category improvement, compared with0% receiving placebo - Improvements in skin disease activity were evident as early as Week 4, increased over time, and were accompanied by benefits on skin-related quality of life
- Brepocitinib was well tolerated during the 16-week study period, with no serious adverse events (SAEs)
- Findings support ongoing Phase 3 BEACON+ study in cutaneous sarcoidosis; topline data expected in calendar year 2028
- Results of the study will be shared by Dr. Misha Rosenbach, MD, in an oral presentation at ACR Convergence 2026 today, November 10
DURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with
CS is an inflammatory granulomatous skin disease affecting approximately 40,000 adults in the United States. The condition disproportionately impacts Black Americans, and unlike most inflammatory skin diseases, can rapidly cause permanent scarring and destruction of bone, cartilage, and hair follicles. Despite this significant unmet therapeutic need, there are currently no FDA-approved therapies for CS.
“Cutaneous sarcoidosis is often on the face and severely impacts patients, and there are no approved treatments,” said Dr. Misha Rosenbach, MD, Professor of Dermatology and Rheumatology and Director of the Cutaneous Sarcoidosis Program at the Hospital of the University of Pennsylvania. “This is the largest study in skin sarcoidosis to date, and the result were striking – seeing clear or almost clear skin in more than two-thirds of patients on brepocitinib demonstrates dramatic improvement and was backed by multiple metrics showing this improved patients’ symptoms and quality of life. These published findings bring rigorous clinical evidence to a historically neglected disease and patient population and offer a compelling reason to believe that a fundamentally different future with more targeted, effective treatments may be possible for our patients.”
The publication, “Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial,” reports results from the Phase 2 dose-ranging portion of BEACON. Thirty-one adults were randomized to brepocitinib 45 mg (n=13), brepocitinib 15 mg (n=11), or placebo (n=7), administered once daily, for 16 weeks of double-blinded treatment.
Both brepocitinib doses demonstrated improvement on the primary endpoint, change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score at Week 16. Mean reductions were 22.3 points with 45 mg and 22.2 points with 15 mg, compared with 0.7 points with placebo (P<0.0001 for each comparison). Improvements were evident by Week 4 and increased through Week 16. Across increasingly stringent responder-based and cutaneous remission-oriented endpoints, efficacy consistently favored brepocitinib 45 mg, supporting a dose-dependent treatment effect.
Additional Week 16 findings for brepocitinib 45 mg included:
- Clear or Almost Clear skin:
69.2% achieved a Cutaneous Sarcoidosis Activity-Investigator Global Assessment score of “Clear” or “Almost Clear,” with at least a two-category improvement, compared with0% on placebo. - At least
50% improvement in skin disease activity:76.9% achieved a reduction of at least50% in CSAMI-A, compared with0% on placebo. - At least a 10-point improvement in CSAMI-A:
100% achieved a reduction of at least 10 points in CSAMI-A, compared with14.3% on placebo. - Low residual skin disease activity:
61.5% achieved a CSAMI-A score less than 5, compared with0% on placebo.
Participants receiving brepocitinib 45 mg also reported improvements in skin-related quality of life. Mean improvement on Skindex-16 was 23.5 points, compared with an 8.9-point worsening on placebo. All participants receiving brepocitinib 45 mg reported improvement on the Patient Global Impression of Change, compared with
Brepocitinib was well tolerated during the study treatment period, with no serious adverse events (SAEs).
Priovant is evaluating brepocitinib 45 mg once daily for CS in the ongoing Phase 3 portion of the BEACON study (BEACON+). Topline data from BEACON+ is expected in calendar year 2028.
About BEACON +
BEACON+ is the Phase 3 portion of the BEACON trial evaluating brepocitinib in patients with cutaneous sarcoidosis. BEACON+ is enrolling approximately 140 patients with cutaneous sarcoidosis across ~70 sites globally. Patients will be randomized 3:2 between brepocitinib 45mg once daily and placebo. The primary endpoint is the proportion of patients achieving a
About Priovant
Priovant Therapeutics is a biotechnology company dedicated to developing and commercializing novel therapies for autoimmune diseases with high morbidity and few available treatment options. The company’s commercial product, LISRAYA™ (brepocitinib), is the first and only targeted oral therapy approved for the treatment of adults with dermatomyositis. See important LISRAYA safety information, including boxed warning, at lisrayahcp.com/pi. Brepocitinib, a first-in-class TYK2/JAK1 inhibitor, recently generated positive Phase 3 data in non-infectious uveitis (NIU). In addition to the phase 3 program in cutaneous sarcoidosis, brepocitinib is also under evaluation in a Phase 2b/3 program in lichen planopilaris. These potential indications have not been approved by the FDA. Priovant Therapeutics is a Roivant (Nasdaq: ROIV) company.
Contact
Stephanie Lee: stephanie.lee@priovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Priovant's Phase 2 BEACON trial show for brepocitinib in cutaneous sarcoidosis?
Both brepocitinib doses improved the primary skin disease activity endpoint at Week 16 versus placebo. Mean reductions were 22.3 points with 45 mg and 22.2 points with 15 mg, compared with 0.7 points with placebo; both comparisons had P<0.0001.
When are Priovant's Phase 3 BEACON+ results expected?
Priovant expects topline results from BEACON+ in calendar year 2028. The ongoing study evaluates brepocitinib 45 mg once daily in cutaneous sarcoidosis.
How is Priovant's Phase 3 BEACON+ trial designed?
BEACON+ is enrolling approximately 140 patients across approximately 70 sites globally, with patients randomized 3:2 to brepocitinib 45 mg once daily or placebo. Its primary endpoint is the proportion achieving at least a 50% reduction in the skin disease activity score at Week 16.
How many patients received each treatment in Priovant's Phase 2 BEACON trial?
The trial randomized 13 adults to 45 mg, 11 to 15 mg and seven to placebo. Each treatment was administered once daily for 16 weeks in a double-blind study, meaning participants and investigators did not know the treatment assignments.